ストックスクリーナーアプリを入手
0.9049
1.59%
-0.0146
アフターアワーズ：
.92
0.0151
+1.67%
前日終値:
$0.9195
開ける：
$0.9077
24時間の取引高:
575.75K
Relative Volume:
0.70
時価総額：
$115.15M
収益：
-
当期純損益:
$-57.09M
株価収益率:
-2.0033
EPS:
-0.4517
ネットキャッシュフロー:
$-51.43M
1週間 パフォーマンス:
+2.17%
1か月 パフォーマンス:
-8.16%
6か月 パフォーマンス:
-65.46%
1年 パフォーマンス:
+38.83%
1日の値動き範囲:
$0.89
$0.9498
1週間の範囲:
$0.89
$0.99
52週間の値動き範囲:
$0.6519
$4.3101
Nautilus Biotechnology Inc Stock (NAUT) Company Profile
名前
Nautilus Biotechnology Inc
セクター
電話
206-333-2001
住所
2701 EASTLAKE AVE EAST, SEATTLE
Compare NAUT vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NAUT
Nautilus Biotechnology Inc
|
0.9049 | 114.82M | 0 | -57.09M | -51.43M | -0.4517 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nautilus Biotechnology Inc Stock (NAUT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-05 | ダウングレード | Goldman | Neutral → Sell |
| 2024-06-27 | 開始されました | Guggenheim | Buy |
| 2024-06-03 | 再開されました | Jefferies | Hold |
| 2022-01-06 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-11-02 | 開始されました | Cowen | Outperform |
| 2021-08-04 | 開始されました | Goldman | Neutral |
| 2021-07-13 | 開始されました | Jefferies | Buy |
すべてを表示
Nautilus Biotechnology Inc (NAUT) 最新ニュース
Nautilus Biotechnology urges new methods to address biological validation challenge in proteomics - Traders Union
Nautilus (NAUT) Watch: Closes 5.82% Higher at $0.90; Technical View: Traders Can Monitor the $0.85-$0.95 Range for the Current SessionSystematic Flow - vinanet.vn
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Sees Significant Increase in Short Interest - MarketBeat
Nautilus Biotechnology Earnings Call Balances Promise and Risk - TipRanks
NAUT Q2 2026 Earnings: Narrower Loss Surprise Lifts Shares 22%Earnings Deceleration Risk - vinanet.vn
Perceptive Advisors group reports 9.1% Nautilus (NAUT) ownership in updated 13D/A - Stock Titan
Nautilus Biotechnology (NAUT) Slides 3.9% to $0.86, Approaching Key Support LevelLiquidity Order Flow - vinanet.vn
Nautilus Biotechnology (NAUT) Steadies Near $0.89 as Support HoldsUpthrust Pattern - vinanet.vn
Nautilus Biotechnology Inc (NASDAQ: NAUT) Share Price, NAUT Stock News, NAUT Share Price & Updates - Kalkine
Nautilus Biotechnology (NAUT) Institutional Ownership 2026 - MarketBeat
Nautilus Biotechnology unveils new proteomics approach for dementia studies - Traders Union
Nautilus Biotechnology: A Contrarian Proteoformics Play After Recent Pullback (NAUT) - Seeking Alpha
Nautilus Biotechnology, Inc. Revenue Breakdown – NASDAQ:NAUT - TradingView
Short Interest in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Rises By 74.6% - MarketBeat
Nautilus Biotechnology sets 31 July deadline for Iterative Mapping Grant Program applications - tradersunion.com
Nautilus Biotechnology Inc (NAUT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nautilus Biotechnology, Inc. 2026: Revenue $190K, EPS ($0.11) — 10-Q Summary - tradingview.com
Nautilus Biotechnology Q2 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Nautilus Biotechnology beats Q2 2026 EPS forecast - Investing.com
Nautilus Biotechnology Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Nautilus Biotechnology posts first revenue, Q2 net loss narrows - TradingView
Nautilus Biotechnology (NASDAQ: NAUT) shifts roadmap after Q2 2026 results - Stock Titan
Nautilus Biotechnology Reports Second Quarter 2026 Financial Results - Yahoo Finance
Nautilus Biotechnology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
NAUT|Nautilus Biotechnology Inc|Price:0.977|Chg%:-0.053 - TradingKey
Nautilus Biotechnology reports Q2 2026: $0.2M revenue, $14.5M net loss, $129.2M cash - TradingView
Nautilus Biotechnology Reports $190,000 Revenue in Second Quarter 2026 - Quiver Quantitative
Nautilus Biotechnology (NAUT) Plunges 25%: Key Levels to Watch After Steep DeclineThrowback Trade - dars.gov.et
Price to earnings forward of Nautilus Biotechnology, Inc. – NASDAQ:NAUT - TradingView
Nautilus Biotechnology Inc (NAUT) Cash Flow - TradingKey
Nautilus Biotechnology Inc (NAUT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NAUT|Nautilus Biotechnology Inc|Price:1.690|Chg%:-0.080 - TradingKey
Nautilus Biotechnology Inc (NAUT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
NAUT|Nautilus Biotechnology Inc|Price:0.980|Chg%:-0.005 - TradingKey
Nautilus Biotechnology Inc (NAUT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nautilus Biotechnology Inc (NAUT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NAUT|Nautilus Biotechnology Inc|Price:1.670|Chg%:-0.020 - TradingKey
Nautilus Biotechnology Inc (NAUT) Risk Assessment: Volatility, Financial Risk & Investment Risk - tradingkey.com
Nautilus Biotechnology Inc (NAUT) Institutional Confidence - TradingKey
TradingKey - TradingKey
Nautilus Biotechnology Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Nautilus Biotechnology (NAUT) to Post Earnings on Tuesday - MarketBeat
Nautilus Biotechnology invites project proposals for Tau Proteoforms Assay grant program - Traders Union
Nautilus Biotechnology (NAUT) Surges 6.1%: Breakout Above Key Support Zone Triggers Buying MomentumCTA Positioning - dars.gov.et
Nautilus Biotechnology2026 Funding Rounds & List of Investors - Tracxn
Nautilus Biotechnology (NAUT) Stages a Recovery: Can the Breakout Hold?Bullish Percent Index - vinanet.vn
Nautilus Biotechnology (NAUT) Posts Modest Decline as Shares Hover Near Support ZoneTrade Entry Signals - vinanet.vn
Nautilus Biotechnology And 2 Promising Penny Stocks To Consider - Sahm
Nautilus Biotechnology (NAUT) Holds Steady Near Support as Biotech Sector Faces Mixed SentimentOBV Divergence - dars.gov.et
Nautilus Biotechnology to present single molecule proteomics webinar on Voyager Platform - Traders Union
Nautilus Biotechnology to announce Q2 2026 results on July 28 - scanx.trade
Nautilus Biotechnology Inc (NAUT) 財務データ
収益
当期純利益
現金流量
EPS
Nautilus Biotechnology Inc (NAUT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Patel Sujal M | CEO, President, and Secretary |
Mar 04 '26 |
Buy |
2.61 |
25,000 |
65,238 |
10,366,721 |
| Suzuki Kentaro | Chief Marketing Officer |
Nov 06 '25 |
Buy |
1.49 |
4,000 |
5,960 |
4,000 |
| Patel Sujal M | CEO, President, and Secretary |
Sep 08 '25 |
Buy |
0.68 |
83,500 |
57,031 |
10,341,721 |
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):